{"id":36706,"date":"2014-09-16T08:36:11","date_gmt":"2014-09-16T12:36:11","guid":{"rendered":"http:\/\/asweetlife.org\/?post_type=news&p=36706"},"modified":"2015-12-30T05:28:18","modified_gmt":"2015-12-30T10:28:18","slug":"novo-nordisks-tresiba-safe-for-children-with-type-1-diabetes","status":"publish","type":"post","link":"https:\/\/asweetlife.org\/?p=36706","title":{"rendered":"Novo Nordisk’s Tresiba Safe for Children with Type 1 Diabetes"},"content":{"rendered":"
\"\"<\/a>Today, at the 50th\u00a0Annual Meeting of the European Association for the Study of Diabetes (EASD), Novo Nordisk announced new data from the BEGIN\u00ae\u00a0YOUNG 1 trial. The study investigates once-daily Tresiba\u00a0(insulin degludec) versus basal insulin Levemir (detemir), both in combination with bolus insulin Novolog (aspart) in a 52-week trial in children and adolescents with type 1 diabetes. This trial is the first to look into the long-term safety of Tresiba\u00a0in children and adolescents (from age 1 to less than 18 years) and the results show that Tresiba\u00a0in combination with Novolog (Novorapid) effectively improved long-term glycemic control.<\/div>\n
\n
\u00a0<\/div>\n
Tresiba\u00a0is a once-daily basal insulin that provides an ultra-long duration of action beyond 42 hours. It is important for people with type 1 and type 2 diabetes to establish a routine for insulin treatment. \u00a0On occasions when administration at the same time of day is not possible, Tresiba\u00a0allows for flexibility in day-to-day dosing time.<\/div>\n

\u00a0<\/p>\n

The BEGIN\u00a0YOUNG 1 trial was a randomized controlled, 26 week open-label, treat-to-target trial (with a 26-week extension) investigating the efficacy and safety of Tresiba, given once daily, and insulin detemir, given once or twice daily, both in combination with bolus insulin aspart in children and adolescents with type 1 diabetes.<\/p>\n

Tresiba\u00a0met the primary endpoint of non-inferiority to Levemir (insulin detemir) for mean change in HbA1c\u00a0(p<0.05) at 26 weeks. In the 26-week extension a lower insulin dose and a significantly greater reduction in fasting plasma glucose (FPG) versus Levemir (p<0.05) was achieved. Both regimens had similar rates of overall and nocturnal hypoglycemia, the rate of severe hypoglycemia was numerically higher with insulin\u00a0Tresiba\u00a0plus Novolog. Of note, patients on Tresiba\u00a0had significantly lower rates of hyperglycaemia with ketosis (p<0.05). Weight\u00a0increased with Tresiba\u00a0and remained unchanged with Levemir. Adverse event profiles were similar for Tresiba and Levemir.<\/p>\n

\u00a0<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Today, at the 50th Annual Meeting of the European Association for the Study of Diabetes (EASD), Novo Nordisk announced new data from the BEGIN\u00ae YOUNG 1 trial. The study investigates once-daily Tresiba (insulin degludec) versus basal insulin Levemir (detemir), both in combination with bolus insulin Novolog (aspart) in a 52-week trial in children and adolescents with type 1 diabetes. This trial is the first to look into the long-term safety of Tresiba in children and adolescents (from age 1 to less than 18 years) and the results show that Tresiba in combination with Novolog (Novorapid) effectively improved long-term glycemic control.<\/p>\n","protected":false},"author":131,"featured_media":36707,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"","_relevanssi_noindex_reason":"","footnotes":""},"categories":[1441],"tags":[1257],"yoast_head":"\nNovo Nordisk's Tresiba Safe for Children with Type 1 Diabetes<\/title>\n<meta name=\"description\" content=\"The trial is the first to look into the long-term safety of Tresiba in children and adolescents and the results show Tresiba safe and improved long-term glycemic control.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/asweetlife.org\/?p=36706\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"ASweetLife Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/asweetlife.org\/?p=36706\",\"url\":\"https:\/\/asweetlife.org\/?p=36706\",\"name\":\"Novo Nordisk's Tresiba Safe for Children with Type 1 Diabetes\",\"isPartOf\":{\"@id\":\"https:\/\/asweetlife.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/asweetlife.org\/?p=36706#primaryimage\"},\"image\":{\"@id\":\"https:\/\/asweetlife.org\/?p=36706#primaryimage\"},\"thumbnailUrl\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2014\/09\/Novo-Nordisk-Logo1.png\",\"datePublished\":\"2014-09-16T12:36:11+00:00\",\"dateModified\":\"2015-12-30T10:28:18+00:00\",\"author\":{\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585\"},\"description\":\"The trial is the first to look into the long-term safety of Tresiba in children and adolescents and the results show Tresiba safe and improved long-term glycemic control.\",\"breadcrumb\":{\"@id\":\"https:\/\/asweetlife.org\/?p=36706#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/asweetlife.org\/?p=36706\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/asweetlife.org\/?p=36706#primaryimage\",\"url\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2014\/09\/Novo-Nordisk-Logo1.png\",\"contentUrl\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2014\/09\/Novo-Nordisk-Logo1.png\",\"width\":215,\"height\":160,\"caption\":\"Novo Nordisk Logo\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/asweetlife.org\/?p=36706#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/asweetlife.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novo Nordisk’s Tresiba Safe for Children with Type 1 Diabetes\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/asweetlife.org\/#website\",\"url\":\"https:\/\/asweetlife.org\/\",\"name\":\"ASweetLife\",\"description\":\"The Diabetes Magazine\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/asweetlife.org\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585\",\"name\":\"ASweetLife Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g\",\"caption\":\"ASweetLife Team\"},\"url\":\"https:\/\/asweetlife.org\/?author=131\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Novo Nordisk's Tresiba Safe for Children with Type 1 Diabetes","description":"The trial is the first to look into the long-term safety of Tresiba in children and adolescents and the results show Tresiba safe and improved long-term glycemic control.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/asweetlife.org\/?p=36706","twitter_misc":{"Written by":"ASweetLife Team","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/asweetlife.org\/?p=36706","url":"https:\/\/asweetlife.org\/?p=36706","name":"Novo Nordisk's Tresiba Safe for Children with Type 1 Diabetes","isPartOf":{"@id":"https:\/\/asweetlife.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/asweetlife.org\/?p=36706#primaryimage"},"image":{"@id":"https:\/\/asweetlife.org\/?p=36706#primaryimage"},"thumbnailUrl":"https:\/\/asweetlife.org\/wp-content\/uploads\/2014\/09\/Novo-Nordisk-Logo1.png","datePublished":"2014-09-16T12:36:11+00:00","dateModified":"2015-12-30T10:28:18+00:00","author":{"@id":"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585"},"description":"The trial is the first to look into the long-term safety of Tresiba in children and adolescents and the results show Tresiba safe and improved long-term glycemic control.","breadcrumb":{"@id":"https:\/\/asweetlife.org\/?p=36706#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/asweetlife.org\/?p=36706"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/asweetlife.org\/?p=36706#primaryimage","url":"https:\/\/asweetlife.org\/wp-content\/uploads\/2014\/09\/Novo-Nordisk-Logo1.png","contentUrl":"https:\/\/asweetlife.org\/wp-content\/uploads\/2014\/09\/Novo-Nordisk-Logo1.png","width":215,"height":160,"caption":"Novo Nordisk Logo"},{"@type":"BreadcrumbList","@id":"https:\/\/asweetlife.org\/?p=36706#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/asweetlife.org\/"},{"@type":"ListItem","position":2,"name":"Novo Nordisk’s Tresiba Safe for Children with Type 1 Diabetes"}]},{"@type":"WebSite","@id":"https:\/\/asweetlife.org\/#website","url":"https:\/\/asweetlife.org\/","name":"ASweetLife","description":"The Diabetes Magazine","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/asweetlife.org\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585","name":"ASweetLife Team","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/asweetlife.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g","caption":"ASweetLife Team"},"url":"https:\/\/asweetlife.org\/?author=131"}]}},"_links":{"self":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts\/36706"}],"collection":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/users\/131"}],"replies":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=36706"}],"version-history":[{"count":0,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts\/36706\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/media\/36707"}],"wp:attachment":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=36706"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=36706"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=36706"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}